What is Corgi IP Licensing & Royalties ETF's earnings per share (EPS)?

Corgi IP Licensing & Royalties ETF (PTNT) reported diluted earnings per share of $-32.15 for fiscal year 2025. This represents a 68.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Corgi IP Licensing & Royalties ETF Financials

PTNT

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE June

This page shows Corgi IP Licensing & Royalties ETF (PTNT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PTNT FY2025 2026-04-22

Palatin’s financials show a development-stage company sustained by external financing because operating spend still dwarfs customer revenue.

Over the last three valid years, operating cash burn stayed near $30M while revenue stayed below $5M, and capex was negligible, so the reported losses are largely cash losses from ongoing R&D and overhead. In the latest year, cash was down to $2.56M and the current ratio to 0.4x, showing that financing inflows were mainly replacing consumed liquidity rather than building reserves.

The headline gross margin above 90% is not the core economic story, because most spending sits below gross profit rather than in cost of revenue. In the latest full operating year, R&D ran at $22.4M against only $4.49M of revenue, so scale has not yet shifted the business into a self-funding mode.

Liquidity has compressed sharply, with cash falling from $29.9M to $2.56M across the period even after repeated financing inflows. Nearly all liabilities are current in the latest year, which means the balance-sheet strain is concentrated in near-term obligations rather than long-dated debt.

Financial Health Signals

Financial health score pending refresh

We are recalculating Corgi IP Licensing & Royalties ETF's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

Corgi IP Licensing & Royalties ETF generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-32.15

YoY+68.2%

Corgi IP Licensing & Royalties ETF earned $-32.15 per diluted share (EPS) in fiscal year 2025. This represents an increase of 68.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$2.6M

YoY-73.1%

5Y CAGR-50.1%

10Y CAGR-21.1%

Corgi IP Licensing & Royalties ETF held $2.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

929,597

YoY+159.3%

Corgi IP Licensing & Royalties ETF had 929,597 shares outstanding in fiscal year 2025. This represents an increase of 159.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$14.9M

YoY-33.5%

5Y CAGR+1.3%

10Y CAGR-4.9%

Corgi IP Licensing & Royalties ETF invested $14.9M in research and development in fiscal year 2025. This represents a decrease of 33.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Corgi IP Licensing & Royalties ETF invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

PTNT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0-100.0%	$4.5M-7.5%	$4.9M+230.5%	$1.5M	N/A	$118K
Cost of Revenue	N/A	$98K-76.7%	$418K+92.4%	$218K+47.1%	$148K	$0
Gross Profit	N/A	$4.4M-1.0%	$4.4M+254.6%	$1.3M+471.8%	-$336K-385.1%	$118K
R&D Expenses	$14.9M-33.5%	$22.4M-1.0%	$22.6M+6.1%	$21.3M+65.0%	$12.9M-7.4%	$14.0M
SG&A Expenses	$7.8M-36.4%	$12.3M-19.8%	$15.3M-7.4%	$16.5M-4.8%	$17.3M+77.5%	$9.8M
Operating Income	N/A	-$22.5M+30.7%	-$32.5M+11.3%	-$36.6M-9.6%	-$33.4M-41.4%	-$23.6M
Interest Expense	$15K-12.2%	$17K-14.5%	$20K-32.6%	$30K+26.6%	$23K+16.4%	$20K
Income Tax	N/A	$0+100.0%	-$4.7M	$0	N/A	$0
Net Income	N/A	-$29.7M-23.7%	-$24.0M+33.6%	-$36.2M-7.7%	-$33.6M-49.8%	-$22.4M
EPS (Diluted)	$-32.15+68.2%	$-101.16	N/A	N/A	N/A	$-0.10

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$3.9M+3278.8%	$116K-98.7%	$8.8M	N/A	$0	N/A	$0	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.5M-18.6%	$4.3M+71.0%	$2.5M	N/A	$3.8M+9.5%	$3.4M-40.3%	$5.7M	N/A
SG&A Expenses	$2.0M-36.5%	$3.1M+88.2%	$1.7M	N/A	$1.5M-12.4%	$1.7M-16.8%	$2.0M	N/A
Operating Income	-$1.6M+78.4%	-$7.3M-257.2%	$4.7M	N/A	-$4.8M-84.3%	-$2.6M+66.4%	-$7.8M	N/A
Interest Expense	$1K+154.6%	$498-75.1%	$2K	N/A	$2K-52.8%	$4K-36.0%	$6K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.4M+80.3%	-$7.3M-255.3%	$4.7M	N/A	-$4.8M-97.0%	-$2.4M+68.8%	-$7.8M	N/A
EPS (Diluted)	$-0.37+87.1%	$-2.86-167.1%	$4.26	N/A	$-9.13-54.2%	$-5.92+70.0%	$-19.71	N/A

PTNT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$3.3M-69.6%	$10.7M-40.1%	$17.9M-50.3%	$36.1M-46.4%	$67.3M-20.9%	$85.1M
Current Assets	$2.9M-70.1%	$9.8M-40.1%	$16.3M-52.8%	$34.6M-47.5%	$65.9M-21.2%	$83.6M
Cash & Equivalents	$2.6M-73.1%	$9.5M-13.2%	$11.0M-63.3%	$29.9M-50.2%	$60.1M-27.5%	$82.9M
Inventory	N/A	$0-100.0%	$526K-44.3%	$944K-18.7%	$1.2M	$0
Accounts Receivable	$0	$0-100.0%	$2.9M+63.8%	$1.8M+12.6%	$1.6M	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.0M-25.9%	$10.9M-44.8%	$19.7M-0.7%	$19.8M+12.2%	$17.6M+261.5%	$4.9M
Current Liabilities	$8.0M-17.1%	$9.7M-36.2%	$15.1M-6.9%	$16.3M+54.7%	$10.5M+167.6%	$3.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$4.8M-4184.5%	-$111K+94.4%	-$2.0M-112.2%	$16.3M-67.2%	$49.7M-38.1%	$80.2M
Retained Earnings	-$459.1M-3.9%	-$441.8M-7.2%	-$412.0M-6.2%	-$388.0M-10.3%	-$351.8M-10.6%	-$318.2M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$13.2M-26.2%	$17.9M+108.1%	$8.6M+163.7%	$3.3M-12.4%	$3.7M-13.5%	$4.3M+26.2%	$3.4M-68.2%	$10.7M
Current Assets	$12.8M-26.8%	$17.5M+108.7%	$8.4M+186.7%	$2.9M-9.7%	$3.2M-11.9%	$3.7M+40.5%	$2.6M-73.3%	$9.8M
Cash & Equivalents	$10.2M-29.8%	$14.5M+1037.1%	$1.3M-50.4%	$2.6M+1.7%	$2.5M-26.2%	$3.4M+43.3%	$2.4M-75.0%	$9.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Accounts Receivable	N/A	$1.6M-76.2%	$6.9M	$0	N/A	N/A	N/A	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.6M-59.2%	$6.5M-21.4%	$8.2M+2.2%	$8.0M-20.5%	$10.1M-5.4%	$10.7M-3.7%	$11.1M+2.3%	$10.9M
Current Liabilities	$2.5M-60.0%	$6.3M-22.9%	$8.2M+2.6%	$8.0M-20.3%	$10.0M+5.1%	$9.6M-3.1%	$9.9M+2.1%	$9.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$10.6M-7.6%	$11.5M+2792.5%	$396K+108.3%	-$4.8M+25.2%	-$6.4M-0.1%	-$6.4M+17.0%	-$7.7M-6793.1%	-$111K
Retained Earnings	-$463.1M-0.3%	-$461.7M-1.6%	-$454.4M+1.0%	-$459.1M-0.5%	-$456.8M-1.1%	-$452.0M-0.5%	-$449.6M-1.8%	-$441.8M

PTNT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	-$31.5M-7.5%	-$29.3M+2.2%	-$29.9M-31855.8%	-$94K-100.2%	$41.3M
Capital Expenditures	$0-100.0%	$43K-90.2%	$434K+66.0%	$261K+4467.9%	$6K-90.9%	$63K
Free Cash Flow	N/A	-$31.5M-6.1%	-$29.7M+1.6%	-$30.2M-30278.5%	-$99K-100.2%	$41.3M
Investing Cash Flow	$3.1M-74.9%	$12.5M+463.3%	-$3.4M-1211.1%	-$261K-4467.9%	-$6K+90.9%	-$63K
Financing Cash Flow	$11.2M-45.4%	$20.5M+91.2%	$10.7M+58449.9%	$18K+100.1%	-$22.6M-1078.5%	-$1.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$4.4M+8.1%	-$4.8M-196.8%	-$1.6M+60.4%	-$4.1M+23.6%	-$5.4M-10.5%	-$4.8M+30.9%	-$7.0M-8.4%	-$6.5M
Capital Expenditures	$38K	N/A	N/A	$0	$0	N/A	N/A	$5K
Free Cash Flow	-$4.5M	N/A	N/A	-$4.1M+23.6%	-$5.4M	N/A	N/A	-$6.5M
Investing Cash Flow	-$38K	N/A	N/A	$630K	$0-100.0%	$2.5M	$0+100.0%	-$5K
Financing Cash Flow	$139K-99.2%	$18.0M+5391.4%	$328K-90.6%	$3.5M-21.4%	$4.5M+31.9%	$3.4M+2761.7%	-$127K-102.1%	$6.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PTNT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	97.8%+6.5pp	91.4%+6.2pp	85.2%	N/A	100.0%
Operating Margin	N/A	-501.0%+167.7pp	-668.8%+1822.9pp	-2491.6%	N/A	-20007.6%
Net Margin	N/A	-662.3%-167.0pp	-495.2%+1969.8pp	-2465.1%	N/A	-19006.9%
Return on Equity	N/A	N/A	N/A	-222.5%-154.8pp	-67.7%-39.7pp	-28.0%
Return on Assets	N/A	-276.8%-142.8pp	-134.0%-33.6pp	-100.4%-50.4pp	-49.9%-23.5pp	-26.4%
Current Ratio	0.36-0.6	1.01-0.1	1.08-1.0	2.13-4.1	6.27-15.0	21.28
Debt-to-Equity	N/A	N/A	N/A	1.22+0.9	0.36+0.3	0.06
FCF Margin	N/A	-701.6%-89.6pp	-612.0%+1443.5pp	-2055.5%	N/A	34972.4%

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-40.3%+6275.4pp	-6315.8%-6368.5pp	52.8%	N/A	N/A	N/A	N/A	N/A
Net Margin	-36.5%+6223.5pp	-6260.0%-6313.0pp	53.0%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-13.5%+49.8pp	-63.3%-1243.4pp	1180.0%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-10.8%+29.7pp	-40.5%-94.8pp	54.3%	N/A	-129.0%-72.4pp	-56.7%+172.4pp	-229.1%	N/A
Current Ratio	5.04+2.3	2.76+1.7	1.02+0.7	0.36+0.0	0.32-0.1	0.38+0.1	0.26-0.7	1.01
Debt-to-Equity	0.25-0.3	0.56-20.2	20.73	N/A	N/A	N/A	N/A	N/A
FCF Margin	-113.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$4.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.36), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Pharmala Biotech MDXXF

$12.9M

Inhibitor Therap INTI

$13.8M

Betterlife Pharma Inc BETRF

$28.6M

Quantum Genomics QNNTF

$7.0M

Bioxytran Inc BIXT

$2.7M

Frequently Asked Questions

What is Corgi IP Licensing & Royalties ETF's annual revenue?

Corgi IP Licensing & Royalties ETF (PTNT) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Corgi IP Licensing & Royalties ETF's revenue growing?

Corgi IP Licensing & Royalties ETF (PTNT) revenue declined by 100% year-over-year, from $4.5M to $0 in fiscal year 2025.

What are Corgi IP Licensing & Royalties ETF's total assets?

Corgi IP Licensing & Royalties ETF (PTNT) had $3.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Corgi IP Licensing & Royalties ETF's capital expenditures?

Corgi IP Licensing & Royalties ETF (PTNT) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Corgi IP Licensing & Royalties ETF spend on research and development?

Corgi IP Licensing & Royalties ETF (PTNT) invested $14.9M in research and development during fiscal year 2025.

How many shares does Corgi IP Licensing & Royalties ETF have outstanding?

Corgi IP Licensing & Royalties ETF (PTNT) had 929,597 shares outstanding as of fiscal year 2025.

What is Corgi IP Licensing & Royalties ETF's current ratio?

Corgi IP Licensing & Royalties ETF (PTNT) had a current ratio of 0.36 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Why is Corgi IP Licensing & Royalties ETF's debt-to-equity ratio negative or not reported?

Corgi IP Licensing & Royalties ETF (PTNT) has negative shareholder equity of -$4.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.